NEW YORK ( TheStreet) -- Questcor Pharmaceuticals (Nasdaq: QCOR) hit a new 52-week high Wednesday as it is currently trading at $44.77, above its previous 52-week high of $44.51 with 249,528 shares traded as of 10:10 a.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Questcor has a market cap of $2.59 billion and is part of the health care sector and drugs industry. Shares are up 190.8% year to date as of the close of trading on Tuesday.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of auto-immune diseases. The company's primary product is H.P. The company has a P/E ratio of 52.9, above the average drugs industry P/E ratio of 50.4 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Questcor as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Questcor Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.